This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
by Zacks Equity Research
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
ABTPositive Net Change MDTPositive Net Change DXCMNegative Net Change TRIBPositive Net Change
medical medical-devices
Should You Buy Mettler-Toledo (MTD) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
MTDPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
by Zacks Equity Research
VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.
REGNPositive Net Change LLYNegative Net Change VERUPositive Net Change SRRKNegative Net Change
medical medical-devices
Accuray Stock Down as Q4 Earnings Miss Estimates, Revenues Down Y/Y
by Zacks Equity Research
ARAY stock down after Q4 earnings miss estimates, with product sales hit by tariffs and regional demand softness.
BSXNegative Net Change ARAYNo Net Change WSTPositive Net Change MEDPPositive Net Change
earnings medical medical-devices
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
by Zacks Equity Research
HQY's HSA growth, AI-driven efficiencies, and strong Q1 results fuel optimism despite data security concerns.
BSXNegative Net Change WSTPositive Net Change HQYNegative Net Change MEDPPositive Net Change
medical medical-devices
Newmark Group (NMRK)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NMRKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Maximus (MMS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
MMSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Phinia (PHIN)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PHINPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Zacks Investment Ideas feature highlights: IonQ, Hims and Hers, Eli Lilly and TransMedics
by Zacks Equity Research
Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.
LLYNegative Net Change TMDXNegative Net Change HIMSPositive Net Change IONQNegative Net Change
computers medical medical-devices pharmaceuticals
4 Medical Product Stocks to Watch From a Challenging Industry
by Indrajit Bandyopadhyay
The Zacks Medical products industry sees steady demand, but tariffs & policy headwinds keep growth under pressure in 2025. NVST, BLFS, INFU and MRMD reflect the favorable fundamentals.
NVSTPositive Net Change BLFSPositive Net Change INFUNegative Net Change MRMDNegative Net Change
medical medical-devices
CVS Advances Digital Efforts to Simplify Healthcare Experience
by Moumi Mondal
CVS Health commits $20B to build an open health platform, joining tech giants in a push to streamline patient care access nationwide.
UNHPositive Net Change WMTNegative Net Change CVSPositive Net Change
medical medical-devices
Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?
by Urmimala Biswas
Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.
IRTCNegative Net Change SOPHNegative Net Change TEMPositive Net Change
artificial-intelligence earnings-outlook earnings-report earnings-surprise healthcare medical medical-devices
Hims & Hers Stock Plunges 21.3% in 3 Months: Time to Hold or Exit?
by Debanjana Dey
HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.
TDOCPositive Net Change AMWLPositive Net Change HIMSPositive Net Change
medical medical-devices
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?
by Ethan Feller
Eli Lilly, CorMedix and Johnson & Johnson represent a diversified mix of healthcare stocks with bullish catalysts
JNJNegative Net Change LLYNegative Net Change CRMDNegative Net Change
biotechnology medical medical-devices pharmaceuticals
After Golden Cross, Brink's (BCO)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
BCOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Janus Henderson Group plc (JHG) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
JHGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue?
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform saw Q2 procedures jump 52% to 35,000, expanding globally as utilization rises despite softer system placements.
SYKNegative Net Change ISRGPositive Net Change GMEDPositive Net Change
medical medical-devices
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength
by Moumi Mondal
HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.
HOLXPositive Net Change MMSIPositive Net Change GEHCPositive Net Change
medical medical-devices
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
by Zacks Equity Research
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
BSXNegative Net Change GMEDPositive Net Change MEDPPositive Net Change WGSPositive Net Change
earnings medical medical-devices
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
BSXNegative Net Change SRDXNegative Net Change WSTPositive Net Change GEHCPositive Net Change
earnings medical medical-devices
Hims & Hers Drives the Consumer-Centric Transformation in Digital Care
by Debanjana Dey
HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.
TDOCPositive Net Change HIMSPositive Net Change DOCSPositive Net Change
medical medical-devices
Reasons to Add Veeva Systems Stock to Your Portfolio for Now
by Zacks Equity Research
VEEV's strong first quarter, product innovations and strategic deals drive growth prospects despite rising costs.
BSXNegative Net Change WSTPositive Net Change VEEVPositive Net Change MEDPPositive Net Change
medical medical-devices
CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls
by Zacks Equity Research
Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
BSXNegative Net Change CAHPositive Net Change WSTPositive Net Change MEDPPositive Net Change
earnings medical medical-devices
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
RAPTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
by Zacks Equity Research
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
BSXNegative Net Change EXASPositive Net Change MEDPPositive Net Change WGSPositive Net Change
earnings medical medical-devices